Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

10-1074

Monoclonal antibody · Antagonist of HIV envelope glycoprotein gp120 · developed by Gilead Sciences

Phase 1 Most advanced trial
1 Registered trials

What is 10-1074?

10-1074 is a monoclonal antibody administered by intravenous infusion. It is being studied in HIV infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
HIV envelope glycoprotein gp120
Mechanism
Antagonist of HIV envelope glycoprotein gp120
Therapy area
Infectious disease
Developer
Gilead Sciences
In trials of
IBRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
L98LJF15I9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04340596 Phase 1 HIV Infection Active not recruiting IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.